Liminal BioSciences, a risky play
85% below the July peak of last year and 99% below its all-time high.
Orbiting a major support level around $4.
A capital injection began in mid-November that is still not properly reflected in price.
Stochastic at the oversold point and RSI close to touching it.
It could give the surprise of giving a significant bounce to the marked lines.
The risk is that it has been trading at a loss for some time.
"Liminal (Nasdaq: LMNL) is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel treatments for patients suffering from diseases that have high unmet medical need, including those related to fibrosis in respiratory, liver and kidney diseases."
Orbiting a major support level around $4.
A capital injection began in mid-November that is still not properly reflected in price.
Stochastic at the oversold point and RSI close to touching it.
It could give the surprise of giving a significant bounce to the marked lines.
The risk is that it has been trading at a loss for some time.
"Liminal (Nasdaq: LMNL) is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel treatments for patients suffering from diseases that have high unmet medical need, including those related to fibrosis in respiratory, liver and kidney diseases."
면책사항
이 정보와 게시물은 TradingView에서 제공하거나 보증하는 금융, 투자, 거래 또는 기타 유형의 조언이나 권고 사항을 의미하거나 구성하지 않습니다. 자세한 내용은 이용 약관을 참고하세요.